GENT: Stock Quote & Summary Data |
Company Description (as filed with the SEC)
We started as a group of pharmaceutical businesses founded in Italy in 1944 and have been involved in the research and development of drugs derived from DNA and DNA molecules since the 1970s. In 1993, we were formed by FinSirton S.p.A. as Pharma Research S.r.L., an Italian private limited company, for the purpose of pursuing research and development activities of prospective pharmaceutical specialty products. In July 2001 we changed our name to Gentium S.p.A.. FinSirton is one of our largest shareholders owning approximately 17% of our outstanding ordinary shares at December 31, 2011, and may be deemed to be controlled by the Dr. Laura Ferro, our former Chief Executive Officer and President and currently one of our directors, and her family. Under our current bylaws, our company’s term of existence will expire on December 31, 2050. We are governed by the Italian Civil Code. ... More ...
Links to all Gentium SpA (GENT) Pages
Stock Analysis
Fundamentals
Holdings
/Ownership
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $0.23 |
| Quarterly EPS Est: | -0.04 |
| PEG Ratio: | -.11 |
| Mean Recommendation: View Summary/View All |
1 |
Data is provided by Zacks Investment Research
Home
Search NASDAQ
Search Web

Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
